A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

ID#: NCT06906471

Age: 18 - 90 years

Gender: Male

Healthy Subjects: No

Study Phase: Phase 1/Phase 2

Recruitment Status: Recruiting

Start Date: July 01, 2026

End Date: December 30, 2026

Contact Information:
Amy Wu, MD
917-960-8876
Summary:

A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS

Eligibility:



Inclusion Criteria:

- suspected prostate cancer warranting standard of care multi-core prostate biopsy

Exclusion Criteria:

- Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment

- Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature

- Patients with a creatinine clearance cutoff (CrCl) of < 60 mL/min

Find a Clinical Trial Find Cancer Clinical Trials